title: Hyperlipidemia and thrombotic complications in patients with membranous nephropathy.
abstract: Membranous nephropathy (MN), the most common cause of adult-onset nephrotic syndrome (NS) in Caucasians, is associated commonly with the secondary complications of hyperlipidemia and hypercoagulability. These may increase the risk for cardiovascular disease, alter the rate of progression of renal disease, and raise the risk for thromboembolic events. The treatment of these secondary effects remains controversial. Although no clear practice guidelines are available to assist the clinician in deciding how and when to start disease-modifying therapies, the literature provides enough information to make reasonable decisions in most clinical scenarios. Prospective trials in the future will provide definitive information on how to best treat these abnormalities.
authors.affiliation: Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Nickolas
authors.forename: Jai
authors.initials: J
authors.lastname: Radhakrishnan
authors.forename: Gerald B
authors.initials: GB
authors.lastname: Appel
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015433:Glomerulonephritis, Membranous / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D019851:Thrombophilia / Q000209:etiology / Q000628:therapy; D013927:Thrombosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy
chemical_list: D000925:Anticoagulants; D000960:Hypolipidemic Agents